Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06679062 · ClinicalTrials.gov registry record · Phase 2

Suvorexant for Treatment of AUD and PTSD

A Phase 2 study of Insomnia and Alcohol Use Disorder (AUD), sponsored by Pharmacotherapies for Alcohol and Substance Use Disorders Alliance.

Recruiting
Registry status
Phase 2
Development phase
76
Enrollment target
2
Study locations

NCT06679062 is a Phase 2 study of Insomnia and Alcohol Use Disorder (AUD) that is actively recruiting participants, run by Pharmacotherapies for Alcohol and Substance Use Disorders Alliance. The registered enrollment target is 76 participants, below the 170-participant average among 151 other Insomnia trials with a reported enrollment target (55% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06679062, a Phase 2 study of Insomnia and Alcohol Use Disorder (AUD), is actively recruiting participants, sponsored by Pharmacotherapies for Alcohol and Substance Use Disorders Alliance.

RECRUITING
Registry status
Phase 2
Development phase
76 participants
Enrollment target
2
Study locations

Study Summary

This study is to determine if suvorexant (SUV) will reduce insomnia in 76 men and women veteran and non-veterans between the ages 21-65 with posttraumatic stress disorder (PTSD) symptoms and alcohol use disorder (AUD). All participants will have a 7-day placebo run-in period, followed by a random assignment to receive placebo or suvorexant for an additonal 14 days. Post-randomization, participants will attempt to stop drinking for two weeks and will complete daily virtual diaries and study outcome assessments via in-person clinic visits on days 7 and 14.

Conditions Studied

Insomnia Alcohol Use Disorder (AUD) Post Traumatic Stress Disorder (PTSD)

Interventions

  • OTHER Placebo
  • DRUG Suvorexant

Study Locations (2)

California

  • University of California - Los Angeles - Los Angeles

Texas

  • The University of Texas Health Science Center - Houston - Houston

Trial Details

FieldValue
Enrollment Target 76 participants
Start Date 2025-07-16
Est. Completion 2026-06
Phase Phase 2

Sponsor

Pharmacotherapies for Alcohol and Substance Use Disorders Alliance

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06679062

The ClinicalTrials.gov registry entry for NCT06679062 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 170-participant average among 151 other Insomnia trials with a reported enrollment target (55% lower). The listed sponsor is Pharmacotherapies for Alcohol and Substance Use Disorders Alliance, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Insomnia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06679062 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Texas.

Frequently Asked Questions

What is clinical trial NCT06679062 about?

NCT06679062 is a clinical study titled "Suvorexant for Treatment of AUD and PTSD". This study is to determine if suvorexant (SUV) will reduce insomnia in 76 men and women veteran and non-veterans between the ages 21-65 with posttraumatic stress disorder (PTSD) symptoms and alcohol use disorder (AUD). All participants will have a 7-day placebo run-in period, followed by a random as...

What is the current status of trial NCT06679062?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2025-07-16. Estimated completion is 2026-06.

What conditions does trial NCT06679062 study?

This clinical trial studies the following conditions: Insomnia, Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD).

What interventions are being tested in trial NCT06679062?

The interventions under investigation include: Placebo (OTHER), Suvorexant (DRUG).

Who is sponsoring clinical trial NCT06679062?

This trial is sponsored by Pharmacotherapies for Alcohol and Substance Use Disorders Alliance, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06679062 being conducted?

This trial has 2 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Insomnia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Insomnia

All registered trials for this condition

Alcohol Use Disorder (AUD)

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.